This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

Trinity Biotech plc (the “Company”) has reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and b2iDigital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment. 

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including, but not limited to, statements related to Trinity Biotech’s financial resources, growth potential, market acceptance and penetration of new or planned products, and future revenues and operations. These statements often include terms such as “may,” “believes,” “projects,” “expects,” “anticipates,” or similar expressions and do not reflect historical facts.

Forward-looking statements are subject to risks, uncertainties, and other factors, including those detailed in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2023, and other periodic filings with the United States Securities and Exchange Commission, available at www.sec.gov. Specific risks include, but are not limited to, Trinity’s ability to achieve its projected financial outcomes, market acceptance of its products, execution of its transformation strategy, reliance on manufacturing and supply chains, and the regulatory approval process for new products.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Trinity Biotech does not undertake and specifically disclaims any obligation to update forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investors are encouraged to consult Trinity’s SEC filings for a complete description of the risks and uncertainties relating to the Company.